http://dx.doi.org/10.1111/j.1600-0447.2009.01464.x
pubmed: 19694628
scopus: 76449083788
Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine
March 2010
Article
| Related Files |
|---|
|
Redirect to Publisher's version
(Publisher's version.url.txt, 50 bytes) |
Abstract. OBJECTIVE: It remains unclear whether unipolar psychotic depression should be treated with an antidepressant and an antipsychotic or with an antidepressant alone. METHOD: In a multi-center RCT, 122 patients (18-65 years) with DSM-IV-TR psychotic major depression and HAM-D-17 > or = 18 were randomized to 7 weeks imipramine (plasma-levels 200-300 microg/l), venlafaxine (375 mg/day) or venlafaxine-quetiapine (375 mg/day, 600 mg/day). Primary outcome was response on HAM-D-17. Secondary outcomes were response on CGI and remission (HAM-D-17). RESULTS: Venlafaxine-quetiapine was more effective than venlafaxine with no significant differences between venlafaxine-quetiapine and imipramine, or between imipramine and venlafaxine. Secondary outcomes followed the same pattern. CONCLUSION: That unipolar psychotic depression should be treated with a combination of an antidepressant and an antipsychotic and not with an antidepressant alone, can be considered evidence based with regard to venlafaxine-quetiapine vs. venlafaxine monotherapy. Whether this is also the case for imipramine monotherapy is likely, but cannot be concluded from the data.
- Male
- Adult
- Aged
- Female
- Humans
- Middle Aged
- Treatment Outcome
- Adolescent
- Severity of Illness Index
- Drug Administration Schedule
- Young Adult
- Drug Therapy, Combination
- Double-Blind Method
- Remission Induction
- Cyclohexanols/*therapeutic use
- Imipramine/*therapeutic use
- Antipsychotic Agents/therapeutic use
- Affective Disorders, Psychotic/*drug therapy
- Antidepressive Agents, Tricyclic/therapeutic use
- Dibenzothiazepines/*therapeutic use
- Drug Dosage Calculations
- Depressive Disorder/*drug therapy
- Serotonin Uptake Inhibitors/therapeutic use